← Back to home

ENDOMETRIAL ATYPICAL HYPERPLASIA/ENDOMETRIOID INTRAEPITHELIAL NEOPLASIA

Clinical trials for ENDOMETRIAL ATYPICAL HYPERPLASIA/ENDOMETRIOID INTRAEPITHELIAL NEOPLASIA explained in plain language.

Never miss a new study

Get alerted when new ENDOMETRIAL ATYPICAL HYPERPLASIA/ENDOMETRIOID INTRAEPITHELIAL NEOPLASIA trials appear

Sign up with your email to follow new studies for ENDOMETRIAL ATYPICAL HYPERPLASIA/ENDOMETRIOID INTRAEPITHELIAL NEOPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1 Not yet finished but already full! 1

New Two-Pronged attack on uterine cancer aims to spare women surgery

Disease control Not yet recruiting

This study is testing if adding a weekly weight-loss injection (tirzepatide) to a hormone-releasing IUD can better treat early-stage uterine cancer or a pre-cancerous condition in women who are overweight or obese. The goal is to see if this combination can eliminate cancer cells…

Matched conditions: ENDOMETRIAL ATYPICAL HYPERPLASIA/ENDOMETRIOID INTRAEPITHELIAL NEOPLASIA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 30, 2026 14:28 UTC

ENDOMETRIAL ATYPICAL HYPERPLASIA/ENDOMETRIOID INTRAEPITHELIAL NEOPLASIA

Get alerted when new ENDOMETRIAL ATYPICAL HYPERPLASIA/ENDOMETRIOID INTRAEPITHELIAL NEOPLASIA trials appear

New Two-Pronged attack on uterine cancer aims to spare women surgery